|
Persistent Mullerian duct syndrome
|
0.800 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
|
Persistent Mullerian duct syndrome
|
0.800 |
Biomarker
|
disease |
CTD_human |
|
|
|
|
Cryptorchidism
|
0.180 |
Biomarker
|
disease |
HPO |
|
|
|
|
Male Pseudohermaphroditism
|
0.140 |
Biomarker
|
disease |
HPO |
|
|
|
|
Hernia, Inguinal
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Male infertility
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Abnormality of male internal genitalia
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Polycystic Ovary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Abbreviations:</b> PCO: polycystic ovaries; HCG: human chorionic gonadotropin; GV: germinal vesicle; MII: metaphase II; IVM: <i>in vitro</i> maturation; IVF: <i>in vitro</i> fertilization; IVC: <i>in vitro</i> culture: MVC: microvibration culture; SC: static culture; ICSI: intracytoplasmic sperm injection; IVM/F-ET: IVM and fertilization-embryo transfer; AMH: anti-Mullerian hormone; OHSS: ovarian hyperstimulation syndrome.
|
31002532 |
2019 |
|
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
<b>Background:</b> Limited evidence exists on the impact of adding a taxane, using endocrine therapy and carrying a deleterious germline <i>BRCA</i> mutation on ovarian reserve measured by anti-müllerian hormone (AMH) levels of young breast cancer patients receiving (neo)adjuvant cyclophosphamide- and anthracycline-based chemotherapy.
|
31355134 |
2019 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
<b>Background:</b> Limited evidence exists on the impact of adding a taxane, using endocrine therapy and carrying a deleterious germline <i>BRCA</i> mutation on ovarian reserve measured by anti-müllerian hormone (AMH) levels of young breast cancer patients receiving (neo)adjuvant cyclophosphamide- and anthracycline-based chemotherapy.
|
31355134 |
2019 |
|
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
<b>Materials and Methods:</b> Patients ≤ 40 years of age with breast cancer and who had known <i>BRCA</i> status and baseline serum AMH level at Samsung Medical Center, Seoul, Korea, were considered for inclusion.
|
31031710 |
2019 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
<b>Materials and Methods:</b> Patients ≤ 40 years of age with breast cancer and who had known <i>BRCA</i> status and baseline serum AMH level at Samsung Medical Center, Seoul, Korea, were considered for inclusion.
|
31031710 |
2019 |
|
Depressive Symptoms
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
(2) A relationship between the level of anti-Müllerian hormone and depressive symptoms was not confirmed in the group of healthy late-reproductive-age women.
|
25826396 |
2015 |
|
DOSAGE-SENSITIVE SEX REVERSAL
|
0.010 |
Biomarker
|
disease |
BEFREE |
Dosage-sensitive sex reversal adrenal hypoplasia congenita critical region on the X chromosome gene 1 (DAX-1) inhibits SF-1-mediated induction of MIS and other steroidogenic genes, whereas Wilms' tumor suppressor gene (WT1) augments SF-1-mediated MIS expression.
|
12213901 |
2002 |
|
Persistent Mullerian duct syndrome
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Persistent müllerian duct syndrome (PMD) with antimüllerian hormone (AMH) deficiency is usually associated with mutations or deletions of the AMH gene, although many cases have no identified gene association.
|
25820398 |
2015 |
|
Polycystic Ovary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
PCOS with AMH >4.6 ng/ml are resistant to HMG stimulation, require dose step up during ART cycles, and are at higher risk for severe OHSS.
|
27978775 |
2018 |
|
Persistent Mullerian duct syndrome
|
0.800 |
Biomarker
|
disease |
BEFREE |
Persistent Müllerian duct syndrome is the result of either anti-Müllerian hormone (AMH) deficiency or AMH receptor resistance.
|
28094762 |
2017 |
|
Polycystic Ovary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Polycystic Ovary Syndrome (PCOS), Diagnostic Criteria, and AMH
|
28240001 |
2017 |
|
Lumbar radiculopathy
|
0.010 |
Biomarker
|
disease |
BEFREE |
Lumbar Radiculopathy in the Setting of Degenerative Scoliosis: MIS Decompression and Limited Correction are Better Options.
|
28600008 |
2017 |
|
Persistent Mullerian duct syndrome
|
0.800 |
Biomarker
|
disease |
BEFREE |
Persistent Müllerian duct syndrome (PMDS) is a rare type of male pseudohermaphroditism caused by a deficiency in anti-Müllerian hormone (AMH) or a defect in its type II receptor.
|
29285121 |
2017 |
|
Persistent Mullerian duct syndrome
|
0.800 |
Biomarker
|
disease |
BEFREE |
Persistent mullerian duct syndrome (PMDS) is a rare form of male pseudohermaphroditism caused by defects in synthesis or actions of mullerian inhibiting factor characterised by persistence of mullerian duct structures in a normal karyotype male.
|
29669771 |
2018 |
|
Persistent Mullerian duct syndrome
|
0.800 |
Biomarker
|
disease |
BEFREE |
Persistent Müllerian Duct syndrome (PMDS) develops due to deficiency of anti-Müllerian hormone (AMH) or insensitivity of target organs to AMH in individuals with 46,XY karyotype.
|
29687786 |
2018 |
|
Carpal Tunnel Syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
Carpal tunnel was related to dialysis vintage and MIS.
|
31546847 |
2019 |
|
Persistent Mullerian duct syndrome
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
PMDS has been attributed to deficient AMH activity or to abnormalities in the AMH receptor.
|
7907140 |
1994 |
|
Testicular dysgenesis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Testicular dysgenesis does not affect expression of anti-müllerian hormone by Sertoli cells in premeiotic seminiferous tubules.
|
8623936 |
1996 |